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Electrical cardioversionAbstract Background: Amiodarone is the only available intravenous antiarrhythmic medication
in Egypt used in acute AF cardioversion. Cardioversion using IV amiodarone takes 6–8 h, and
can be as late as 16 h. The aim of this study was to identify the clinical factors that are most asso-
ciated with early (<8 h) successful pharmacological cardioversion of AF, and use them to construct
a weighted scoring system, that can help in deciding which patient to start with electric cardiover-
sion to reduce time and cost of hospital stay.
Methods: The study included 83 consecutive patients; with first attack, recent onset AF lasting less
than 48 h. The patients were divided into a study group (60 patients), and a validation group (23
patients). The study group patients were divided into Group A (cardioverted in less than
480 min), and group B (cardioverted at 480 min or more), and different clinical and echocardio-
graphic data were collected and compared between the two groups. Relevant variables were entered
in forward binary logistic regression analysis, and weighted score was constructed. The score was
validated on the validation group.
Results: A 7 variable scoring system was constructed as follows: LA diameter <3.35 cm 6 points,
no significant MR 4 points, no history of DM 3 points, mean BP on presentation below 95 mmHg 3
points, presentation before 225 min of onset of symptoms 2 points, no history hypertension 1 point
and no diastolic dysfunction 1 point, with final total score = 20 points. A ROC analysis was per-
formed for the scored patients showing that all patients scoring 12 points or more are most likely to
convert early with a sensitivity of 89.5% and a specificity of 92.7%, P< 0.0001. Score validation
revealed sensitivity, specificity, and accuracy for detection of early cardioversion of 80%, 88% and
83%, P= 0.006 respectively.
Conclusion: The current study suggested a weighted scoring system, to predict the time to car-
dioversion in patients with recent onset first presentation with atrial fibrillation.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).oo.com
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Atrial fibrillation (AF) is the most common single rhythm dis-
order encountered by emergency physicians, and cardiologists,
with a prevalence of up to 5% of the population.1 Hospitaliza-
tion of patients with AF is also very common. Early conver-
sion to sinus rhythm (SR) improves symptoms, prevents the
detrimental effects of prolonged AF, and avoids expenses of
prolonged hospitalization.2 In patient with presumed recent-
onset AF 6 48 h in duration, attempts to restore SR are the
first line option.3 Pharmacological cardioversion of AF to
SR is commonly attempted.4 Amiodarone is an antiarrhythmic
class III agent with unique electrophysiological properties, and
it has been used as an effective antiarrhythmic drug for many
years, and its efficacy is proven in a wide spectrum of atrial and
ventricular arrhythmias.1 In the other hand, it’s the only avail-
able intravenous (IV) antiarrhythmic medication in Egypt
which can be used in acute AF cardioversion. Cardioversion
of recent onset AF can be as late as 16 h, when amiodarone
is used.5 The aim of this work was to identify the clinical fac-
tors that are most associated with early (<8 h) successful
pharmacological cardioversion of AF using IV amiodarone,
and use them to construct a weighted and easily applied clini-
cal scoring system, to determine patients who will mostly con-
vert early (<8 h), and those who will convert later (P8 h),
shortening their hospital stay, by applying an alternative strat-
egy e.g. electrical cardioversion as an initial strategy on
presentation.
2. Patients and methods
The study was carried out in cardiology department Zagazig
university hospitals. The study included consecutive patients
admitted to CCU with recent onset; first attack of AF lasting
less than 48 h. Informed consent was obtained from each
patient. The necessary approvals were obtained from medical
ethics and research committee in Zagazig University. Patients
with hemodynamic instability, heart failure, congenital heart
disease, rheumatic heart disease, acute coronary syndrome,
previous history of embolic events, sick sinus syndrome,
Wolff–Parkinson–White syndrome and contraindications to
amiodarone were excluded from the study. None of the
patients was on any classes I, III, or V antiarrhythmic
medications.
Full clinical evaluation was carried out including the fol-
lowing: evaluation of risk factors, special habits, time from
the first sensation of palpitation, drug history, history of
hypertension and DM. Clinical examination includes General
and local cardiac examination, presentation of blood pressure
and heart rate. Laboratory investigations included the follow-
ing: sodium, potassium, High sensitive troponin and high sen-
sitive C-reactive protein.
All patients were admitted to CCU, monitored and received
amiodarone HCl 150 mg IV infusion bolus, over 20 min, 1
mg/min IV infusion for 8 h, and then 0.5 mg/min IV infusion
for 16 h or until cardioversion. If cardioversion failed for
24 h direct current cardioversion was performed under seda-
tion. Cardioversion, whether pharmacological or electrical,
was followed by oral amiodarone loading. Heart rate control
was achieved by using the following: propranolol IV
0.15 mg/kg and then the patients were maintained onMetoprolol 25–100 mg twice daily, if contraindicated oral Dil-
tiazem or Verapamil was used 120–360 mg daily in divided
doses for both of them. All other aspects of management were
carried out according to ACC/AHA/ESC 2006 Guidelines for
the Management of Patients with Atrial Fibrillation.6
The enrolled patients underwent transthoracic echocardio-
graphy on admission. Echocardiography was performed using
HP Sonos 5500 ultrasound machine (Philips, Netherlands)
using 2.5 MHz transducer. The evaluation was conducted
according to Feigenbaum et al.7 Two-dimensional images from
the standard parasternal long and short axis as well as apical
views were obtained to determine the following: left ventricular
(LV) volumes, ejection fraction (EF), Left atrial diameter,
assessment of diastolic function, detection and assessment of
mitral valve regurgitation (MR), and patients with grade II
and more MR were considered to have significant MR. Linear
left atrial dimension was obtained at end-systole just before
mitral valve opening, using M-mode in the parasternal long
axis view, with the M-mode plane passing through the aortic
valve, the anterior, and the posterior walls of the left atrium.
Evaluation of the left ventricular diastolic function was done
using the following: tissue Doppler imaging obtained from
the medial mitral valve annulus in the apical 4 chamber view.
E/e0 ratio was calculated, and the presence of diastolic dysfunc-
tion is determined if the ratio is more than 15. Evaluation of
mitral regurgitation was done using color Doppler flow, and
apical four chamber and parasternal long axis views were used.
Calculation of the percentage of the regurgitant jet area to the
left atrial area in both views was performed. A percentage less
than 15% was considered grade 1 MR, 15–35% grade 2, 35–
50% grade 3, and more than 50% grade 4. The higher percent-
age of the 2 views is considered, when the jet is stopped by LA
wall at any side, and the grade was increased by one.
During their admission in CCU, heart rate and blood
pressure were monitored. Automated blood pressure measure-
ments were taken every 10 min, blood pressure measurements
were recorded automatically and a trend curve was displayed
and printed from the patient’s monitor. Hourly change of
mean blood pressure was calculated as percentage from the
last recorded measurement for 8 h or until the patient is car-
dioverted. Heart rate was continuously monitored, and auto-
mated heart rate trends were recorded and printed from the
patient’s monitor; the percentage of change from last recording
was calculated every 2 h for the first 8 h of admission or until
cardioversion.
Patients were divided into two groups 1 – a study group
(n= 60 patients) used to construct the scoring system and 2
– a validation group (n= 23 patients) used to validate the
scoring system. The study group was divided according to
the time of cardioversion into two groups: group A included
patients who were cardioverted before 480 min of initiation
of amiodarone infusion, and group B who were cardioverted
at 480 min or more of initiation of amiodarone infusion.
Statistical analysis included comparing different parameters
between study group and validation group, using independent
t-test for numerical variables and chi-square for categorical
variables to insure similarity. Analysis also included compar-
ing different parameters between groups A and B, using inde-
pendent t-test for numerical variables and chi-square for
categorical variables. All significantly different variables were
entered in a forward stepwise binary logistic regression analy-
sis to select the best model. After selecting the best model,
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ROC analysis was performed. The variable chosen in the last
step was weighed using the odds ratios calculated from the
regression coefficient (b) for each variable, the odds ratios were
multiplied by 0.214 to calculate a score for each variable and
the number was rounded to the nearest integer giving of scor-
ing system of 20 points. All study group patients were scored.
The cutoff point of the score was calculated using ROC anal-
ysis. The validation group of patients was scored. The outcome
of the patients was compared to the outcome predicted by the
score, and calculation of sensitivity, specificity and accuracy
was performed. Data were entered checked and analyzed using
SPSS for Windows version 16 (SPSS, Inc. Chicago, IL, USA).
For all the above mentioned statistical tests, the threshold of
significance is fixed at 5% level (P< 0.05).
3. Results
A total of 83 patients were included in this prospective cohort
study, conducted between June 2014 and January 2016. The
study population was divided into a study group and a valida-
tion group, Table 1 shows a comparison between the clinical
characteristics and outcome of the two groups. The two groups
were not different in all clinical aspects and there was no sig-
nificant difference in time to cardioversion or in percentage
of patients converted after 8 h.
In the study group, patients converted early to sinus
rhythm, group A (before 480 min) were 41 patients (68.3%)Table 1 Clinical characteristics and outcome in the study and the v
Study group (n = 60)
Mean ± SD
Age (years) 45.6 ± 9.97
TOSa (min) 354.6 ± 341.47
Mean Blp (mmHg) 94.4 ± 11.21
Initial HR (beats/min) 153.8 ± 13.12
Troponin-T (ng/mL) 0.007 ± 0.0038
HS-CRP (mg/L) 2.9 ± 1.7
Potassium (mg/dl) 4.1 ± 0.32
Sodium (mg/dl) 138.1 ± 2.53
Ejection fraction (%) 62.7 ± 4.96
LA diameter (cm) 3.3 ± 0.48
Corrected QT (ms) 418.4 ± 11.8
Time to cardioversion (min) 447.1 ± 313.93
Score (points) 12.5 ± 4.87
n (%)
Sex (females) 35 (58.3%)
Smokers 12 (20%)
DM 12 (20%)
Hypertension 14 (23.3%)
Dyslipidemia 7 (11.7%)
Medications
ACE-Ib 11 (18.3%)
Statins 8 (13.3%)
Ca-blockers 3 (5%)
b-blockers 2 (3.3%)
Diastolic dysfunction 11 (18.3%)
Mitral regurgitation 7 (11.7%)
ConvertedP 8 h 19 (31.7%)
a Time from onset of symptoms to hospital admission.
b Angiotensin converting enzyme inhibitor.and those converted late, group B (P480 min) were 19 patients
(31.7%). Two patients in group B received DC after 24 h on
amiodarone infusion without cardioversion to SR. Table 2
shows the comparison between the two groups.
From the aforesaid relations, it was clear that time from
onset of symptoms, mean blood pressures, ejection fraction,
left atrial diameter, heart rate change in the third 2 h of admis-
sion and change in blood pressure in the fifth hour of admis-
sion all were significantly different between groups A and B.
We also concluded that sex, smoking, dyslipidemia, ACE-I
intake, statins intake, and calcium channels blockers have no
statistically significant difference between the two groups while
diabetics, hypertensives, patients with diastolic dysfunction,
patients on b blockers, and patients with significant mitral
regurgitation converted late.
The variables entered in the forward stepwise binary logis-
tic regression analysis were 11 variables: history of DM, his-
tory of hypertension, b blockers intake, diastolic
dysfunction, significant MR, time from onset of symptoms,
mean blood pressure at presentation, EF, LA dimension,
change in heart rate in the third 2 h of admission, and change
in heart rate in the 5th hour of admission. Variables selected in
the final step were history of DM, HTN, mean blood pressure
on admission, onset of symptoms, LA dimension, significant
MR and diastolic dysfunction (Table 3). The table shows the
progressive increase in R square and statistical significance
with each step. The overall model accuracy was 100% in pre-
dicting both early and late cardioversion (Cox & Snell R
Square = 0.713, x2 = 0.0113).alidation groups.
Validation group (n = 23) t P
Mean ± SD
43.1 ± 6.67 1.13 0.26
398.9 ± 264.61 0.56 0.58
98.6 ± 11.45 1.53 0.13
148.8 ± 20.11 1.318 0.19
0.007 ± 0.0033 0.661 0.51
3.6 ± 1.99 1.54 0.13
4.2 ± 0.23 1.47 0.15
139.3 ± 1.94 1.96 0.05
62.1 ± 4.75 0.461 0.65
3.2 ± 0.72 0.571 0.57
419.3 ± 10.54 0.435 0.72
533.3 ± 359.37 1.08 0.29
12.6 ± 5.61 0.07 0.94
n (%) x2 P
11 (47.8%) 0.743 0.46
4 (17.4%) 0.73 1
5 (21.7%) 0.031 0.54
7 (30.4% 0.444 0.58
6 (26.1%) 2.617 0.17
4 (17.4%) 0.01 0.90
4 (17.4%) 0.22 0.70
4 (17.4%) 3.31 0.08
2 (8.7%) 1.04 0.31
6 (26.1%) 0.61 0.31
3 (13.0%) 0.03 0.56
10 (43.5%) 1.02 0.32
Table 2 Clinical characteristics of groups A and B.
Group A (N= 41) Group B (N= 19) P
Mean ± SD Mean ± SD
Age (years) 46.5 ± 8.91 43.6 ± 11.95 0.30
TOSa (min) 232 ± 129.3 618 ± 487.5 <0.001
Mean Blp (mmHg) 92.03 ± 10.179 99.4 ± 11.951 0.02
Initial HR (beat/min) 154.2 ± 13.201 152.89 ± 13.262 0.72
Troponin-T (ng/mL) 0.00746 ± 0.003 0.00747 ± 0.003 0.99
HS-CRP (mg/L) 2.693 ± 1.354 3.495 ± 2.2235 0.09
Potassium (mg/dl) 4.09 ± 0.28 4.05 ± 0.38 0.70
Sodium (mg/dl) 138.07 ± 2.40 138.21 ± 2.8 0.80
Ejection fraction (%) 64.2 ± 4.17 59.47 ± 5.08 <0.001
LA diameter (cm) 3.0 ± 0.32 3.7 ± 0.41 <0.001
Corrected QT (ms) 416.51 ± 11.53 422.32 ± 11.68 0.08
HR change in 1st 2H (%) 19 ± 0.11 19 ± 0.15 0.90
HR change in 2nd 2H (%) 15 ± 0.08 16 ± 0.131 0.70
HR change in 3rd 2H (%) 11 ± 0.08 5.1 ± 0.076 0.005
HR change in 4th 2H (%) 5 ± 0.10 4 ± 0.114 0.10
Blp change in 1st H (%) 2 ± 0.07 5 ± 0.081 0.20
Blp change in 2nd H (%) 1.4 ± 0.08 1.9 ± 0.079 0.40
Blp change in 3rd H (%) 5.15 ± 0.06 2.84 ± 0.073 0.20
Blp change in 4th H (%) 0.5 ± 0.05 0.147 ± 0.063 0.70
Blp change in 5th H (%) 1.7 ± 0.04 2.748 ± 0.070 0.005
Blp change in 6th H (%) 0.3 ± 0.03 0.47 ± 0.037 0.70
Blp change in 7th H (%) 2.6 ± 0.05 2.81 ± 0.061 0.10
Blp change in 8th H (%) 0.261 ± 0.06 .0156 ± 0.067 0.80
Time to cardioversion 254.27 ± 115.918 863.16 ± 160.453 <0.001
n (%) n (%) P
Sex (females) 26 (63.4%) 9 (47.4%) 0.27
Smoking 7 (17.1%) 5 (26.3%) 0.49
DM 4 (9.8%) 8 (42.1%) 0.006
Hypertension 4 (9.8%) 10 (52.6%) 0.001
Dyslipidemia 4 (9.8%) 3 (15.8%) 0.67
ACE-Ib 8 (19.5%) 3 (15.8%) 0.76
Statins 4 (9.8%) 4 (21.1%) 0.25
Ca-blockers 2 (4.9%) 1 (5.3%) 0.95
b-blockers 0 (0%) 2 (10.2%) 0.04
Diastolic dysfunction 2 (4.9%) 9 (47.4%) <0.001
Significant MR 2 (4.9%) 5 (26.3%) 0.03
a Time from onset of symptoms.
b Angiotensin converting enzyme inhibitor.
248 H.S. Roshdy et al.The cutoff values of different numeric variables selected in
the model were mean Blp at presentation = 94.8 mmHg with a
sensitivity of 73% and a specificity of 64% with area under the
curve = 0.698. Time from the onset of symptoms to presenta-
tion was 225 min with a sensitivity of 84% and a specificity of
57% with area under the curve = 0.815. LA diameter was
3.35 cm with a sensitivity of 89.5% and a specificity of 86%
with area under the curve = 0.916, for all the three variables
P< 0.05, as shown in ROC analysis curve, Fig. 1.
Variables selected in the final model were scored by calcu-
lating the regression coefficient (b) for each variable. b was
squared giving the odds ratio for each variable. Then the odds
ratios were multiplied by a constant (0.214) and rounded to the
nearest integer to give a 20 point scoring system (Table 4), and
the final score is shown in Table 5.
All patients were scored using the scoring system in Table 5
and a ROC analysis was performed for the scored patients
showing that all patients scoring 12 points or more are most
likely to convert early with a sensitivity of 89.5% and aspecificity of 92.7% with area under the curve = 0.955,
P< 0.001 (Fig. 2).
The validation group was scored. The outcome predicted
by the score was compared with the actual time of cardiover-
sion (Table 6). From the table we can conclude that the current
score has a sensitivity, specificity, accuracy, positive predictive
value and negative predictive value of 80%, 88%, 83%, 92%
and 70% respectively (x2 = 9.673, P= 0.006), in detecting
early (less than 8 h) cardioversion of AF to SR when using
IV amiodarone.
4. Discussion
Previous studies on the ability of IV administered amiodarone
to revert recent onset AF focused mainly on the dose regimen
of amiodarone or compared amiodarone with other antiar-
rhythmic drugs. Thus, the present study is the first prospective
study on the factors affecting time to amiodarone cardiover-
sion in patients with recent onset AF. From a review of the
Table 3 Steps of the forward binary logistic regression, with
progressive increase in model strength as indicated by Cox &
Snell R square and x2.
Steps Variable Cox & Snell R Square x2
Step 1 LA dimension 0.455 4.801
Step 2 LA dimension 0.538 5.655
LV diastolic dysfunction
Step 3 History of HTN 0.592 2.822
LA dimension
LV diastolic dysfunction
Step 4 History of HTN 0.636 0.768
Mean Blp
LA dimension
LV diastolic dysfunction
Step 5 History of HTN 0.713 0.0389
Mean Blp
Onset of palpitation
LA dimension
LV diastolic dysfunction
Step 6 DM 0.713 0.0114
History of HTN
Mean Blp
Onset of palpitation
LA dimension
LV diastolic dysfunction
Step 7 DM 0.713 0.0113
History of HTN
Mean Blp
Onset of palpitation
LA dimension
MR
LV diastolic dysfunction
Figure 1 ROC curve showing the different cutoff points of mean b
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shown to predict the success of cardioversion from AF and
use these to develop a decision protocol. In our study we tried
to assess the clinical factors affecting time to cardioversion on
using amiodarone to cardiovert patients with first attack of
presumed recent onset AF 6 48 h to minimize hospital stay
of the patients, through identifying patients who are most
likely will take longer times to cardiovert using amiodarone,
and consider earlier electric cardioversion in such patients.
It appeared that our selection criteria did not apply equally
across all ages, as the mean age in our study was 45.63 ± 9.97;
however, we thought that factors other than age are more
important predictors of the outcome of cardioversion. A ran-
domized, placebo-controlled study done by Cotter et al.8 noted
that age was not found to be independent predictors for early
amiodarone cardioversion.
We found that heart rate changes took decrescendo pattern
after initiation of IV amiodarone and reached the peak point
of decreasing after 8 h. In the prospective, randomized study
by Delle et al.9 a significant rate reduction was observed after
60 min, the nadir occurring within 3–4 h after drug
administration.
The importance of left atrial size is emphasized in our study
by analysis of those who had baseline echocardiographic stud-
ies as we suggest that the most important factor that affects
time to cardioversion is the left atrial size, we found that there
is an direct relationship between the left atrial size and the time
to cardioversion, as the smaller the left atrium the greater the
likelihood of the early restoration of sinus rhythm. Alp et al.10
noted that of the 46 studies of acute cardioversion identified in
their comprehensive search of clinical trials, only 9 gave infor-
mation relating left-atrial diameter from echocardiography to
success of cardioversion, although the results were not consis-
tent as there was a suggestion of an inverse association
between left-atrial diameter and successful cardioversion.lood pressure, time from onset of symptoms and LA diameter.
Table 4 The variables selected in the last step of the regression analysis with their odds ratios, scores and Wald statistics.
b Odds ratio aScore Rounded score Wald P
Variables LA diameter 5.297 28.055 6.00 6 17.23 <0.001
MR (Grade I or less) 4.105 16.847 3.60 4 15.56 <0.001
DM (No) 3.957 15.656 3.35 3 14.44 <0.001
Mean Blp 3.653 13.342 2.85 3 14.33 <0.001
Onset of palpitation 2.914 8.492 1.82 2 7.34 =0.004
HTN (No) 2.406 5.79 1.24 1 13.12 <0.001
Diastolic dysfunction (No) 2.387 5.7 1.22 1 5.35 =0.017
a Score = odds ratio multiplied by 0.214.
Table 5 Items of the scoring system and their scoring points.
Variable Score
LA diameter < 3.35 cm 6
MR grade I or less 4
No Diabetes 3
Mean BP on presentation below 95 mmHg 3
Presentation before 225 min of onset of symptoms 2
No hypertension 1
No diastolic dysfunction 1
Total score 20
Figure 2 ROC curve showing the cutoff point of the new scoring
system.
Table 6 Cross table showing the real outcome versus the score predict
Score predicted
<8 h P8 h
Outcome <8 h 12 (80.0%) 1 (12.
P8 h 3 (20.0%) 7 (87.
Total 15 (100.0%) 8 (100
250 H.S. Roshdy et al.Strikingly, we observed that MR grade II or more had a
significant effect on the time of cardioversion using amio-
darone in patient with recent onset AF 6 48 h. in duration
as we noticed patients with MR grade II or more cardiovert
to SR later. Although, there are no efficient data in the litera-
ture that investigate the effect of mitral resurge on the time of
amiodarone cardioversion in patients with recent onset AF but
Pisters et al.11 observed that both hypertension and coronary
artery disease are positively associated with IV pharmacologi-
cal cardioversion success as opposed to heart failure and MR.
Also, we noticed that diastolic dysfunction appears to influ-
ence the time of amiodarone cardioversion as patients with
normal LV diastolic function had early cardioversion using
amiodarone. Wyse et al.12 suggest that patients with AF suffer-
ing from diseases associated with impaired diastolic LV func-
tion (hypertension, coronary heart disease, diabetes, and
hypertrophic cardiomyopathy) demonstrate more resistance
to pharmacological cardioversion.
In our prospective cohort study we noted that patients with
diabetes mellitus have less opportunity for early cardioversion
of recent onset AF than non-diabetic patients. From review of
literature we didn’t find any studies that addressed that issue
directly. But it appears that the association between inflamma-
tion and DM13 may be a strong candidate to explain, why the
diabetic patients fail to cardiovert as well as fail to maintain
SR after cardioversion compared to non-diabetics.14,15
According to the relative weights of different significant
variables in the regression analysis and depending on the cut-
off values from the ROC analysis we found that arterial hyper-
tension and Mean Blood pressure on presentation below
95 mmHg have a significant role in the prediction of early car-
dioversion. A study done by Kaluzay et al.16 matched with our
result as they suggest that BP immediately prior to cardiover-
sion influences the success of the procedure, and subjects with
successful cardioversion had BP prior to the procedure closer
to BP 120/80 mmHg.
Our analysis did not confirm a correlation between the time
of amiodarone cardioversion and dyslipidemia, and the intakeed outcome (the datawere expressed as number of patients and%).
Total x2 P
5%) 13 (56.5%) 9.673 0.006
5%) 10 (43.5%)
.0%) 23 (100.0%)
Detection of early cardioversion using intravenous amiodarone 251of statins had no statistically significant difference in the time
of cardioversion. Despite the results of Tveit et al.17 suggest
that lipid-lowering drug use is associated with a significant
reduction in AF risk, the role of lipid-lowering drugs in the
treatment of preexisting AF is not elucidated by this study
and remains controversial.
In this study we found that smoking has no significant
effect on time of amiodarone cardioversion. Although there
are no sufficient data on the effect of smoking on the time of
cardioversion, the findings of the prospective study done by
Kinoshita et al.18 show for the first time, a risk of recurrent
atrial arrhythmia associated with smoking.
Indeed, we notice that there is no association between the
use of calcium channels blockers, and time of cardioversion.
These results are in harmony with those of Tieleman et al.19
who noted that there were no significant differences between
patients with or without concomitant treatment with calcium
channel blockers especially verapamil and early cardioversion
of recent onset AF.
Finally, data on predictors of pharmacological cardiover-
sion are scarce and conflicting. However, shorter duration of
AF and smaller left atrial dimension are probably the most
consistently identified as predictors of successful pharmacolog-
ical cardioversion.11
In summary, we have developed a decision protocol to
identify patients presenting with AF in whom cardioversion
by pharmacological or electrical means is usually successful.
We would encourage more frequent use of cardioversion in
the management of atrial fibrillation, particularly if the
arrhythmia is of recent onset and the conditions of our proto-
col are met. We hope that by using our score, we can minimize
hospital stay of the patients, through identifying patients who
are most likely will take longer times to cardiovert using amio-
darone, and start with electric cardioversion in such patients,
that will have important implications in terms of bed manage-
ment and cost-effectiveness.5. Study limitations
The main limitation of this study is that the evidence of recent
onset AF is subjective not objective as it depends on symp-
tomatology only which may be variant from patient to patient.
The other main limitation is there is no placebo arm in this
study and we do not know what the placebo cardioversion rate
would have been. We acknowledge that there are no enough
data from previous studies about the same subjects and also
sample size is of limited number.6. Conclusions
We developed a 20 point scoring system for detection of <8 h
cardioversion of recent onset first attack AF using intravenous
amiodarone, as follows: LA diameter <3.35 cm scores 6
points, no significant MR scores 4 points, no history of DM
scores 3 points, mean BP on presentation below 95 mmHg
scores 3 points, presentation before 225 min of onset of symp-
toms scores 2 points, no history hypertension scores 1 point,
and no diastolic dysfunction scores 1 point with final total
score = 20 points, and a cutoff score of 12 points. This scoring
system can help clinician to decide which patient to start withpharmacological cardioversion using IV amiodarone, and
which patient to start with electric cardioversion.
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